American Journal of Ophthalmology
Volume 149, Issue 1 , Pages 147-154 , January 2010

Pegaptanib Sodium for Macular Edema Secondary to Branch Retinal Vein Occlusion

  • John J. Wroblewski

      Affiliations

    • Cumberland Valley Retina Consultants, Hagerstown, Maryland
    • Corresponding Author InformationInquiries to John J. Wroblewski, Cumberland Valley Retina Consultants, 1150 Opal Court, Hagerstown, MD 21740
    • ,
  • John A. Wells III

      Affiliations

    • Palmetto Retina Center, Columbia, South Carolina
    • ,
  • Christine R. Gonzales

      Affiliations

    • Retina and Vitreous Center of Southern Oregon, Ashland, Oregon

,Accepted 5 August 2009.

References 

  1. Jefferies P, Clemett R, Day T. An anatomical study of retinal arteriovenous crossings and their role in the pathogenesis of retinal branch vein occlusions. Aust N Z J Ophthalmol. 1993;21:213–217
  2. Frangieh GT, Green WR, Barraquer-Somers E, Finkelstein D. Histopathologic study of branch retinal vein occlusion. Arch Ophthalmol. 1982;100:1132–1140
  3. Trope GE, Lowe GD, McArdle BM, et al. Abnormal blood viscosity and haemostasis in long-standing retinal vein occlusion. Br J Ophthalmol. 1983;67:137–142
  4. McGrath MA, Wechsler F, Hunyor AB, Penny R. Systemic factors contributory to retinal vein occlusion. Arch Intern Med. 1978;138:216–220
  5. Janssen MCH, de Heijer M, Cruysberg JRM, Wollersheim H, Bredie SJH. Retinal vein occlusion: A form of venous thrombosis or a complication of atherosclerosis?. Thromb Haemost. 2005;93:1021–1026
  6. Rehak J, Rehak M. Branch retinal vein occlusion: pathogenesis, visual prognosis, and treatment modalities. Curr Eye Res. 2008;33:111–131
  7. Margolis R, Singh RP, Kaiser PK. Branch retinal vein occlusion: clinical findings, natural history, and management. Compr Ophthalmol Update. 2006;7:265–276
  8. McIntosh RL, Mohamed Q, Saw SM, Wong TY. Interventions for branch retinal vein occlusion: an evidence-based systematic review. Ophthalmology. 2007;114:835–854
  9. Branch Vein Occlusion Study Group. Argon laser scatter photocoagulation for prevention of neovascularization and hemorrhage in branch vein occlusion. Arch Ophthalmol. 1986;104:34–41
  10. Gutman FA, Zegarra H. The natural course of temporal retinal branch vein occlusion. Trans Am Acad Ophthalmol Otolaryngol. 1974;78:OP178–OP192
  11. Hayreh SS, Rojas P, Podhajsky P, Montague P, Woolson RF. Ocular neovascularization with retinal occlusion: III. Incidence of neovascularization with retinal vascular occlusion. Ophthalmology. 1983;90:488–506
  12. Gutman FA. Macular edema in branch retinal vein occlusion: prognosis and management. Trans Sect Ophthalmol Am Acad Ophthalmol Otolaryngol. 1977;83:488–495
  13. Houtsmuller AJ, Vermeulen JA, Klompe M, et al. The influence of ticlopidine on the natural course of retinal vein occlusion. Agents Actions Suppl. 1984;15:219–229
  14. Glacet-Bernard A, Coscas G, Chabanel A, Zourdani A, Lelong F, Samama MM. A randomized, double-masked study on the treatment of retinal vein occlusion with troxerutin. Am J Ophthalmol. 1994;118:421–429
  15. Poupard P, Eledjam JJ, Dupeyron G, et al. Role of acute normovolemic hemodilution in treating retinal venous occlusions. Ann Fr Anesth Reanim. 1986;5:229–233
  16. Hansen LL, Wiek J, Arntz R. Randomized study of the effect of isovolemic hemodilution in retinal branch vein occlusion. Fortschr Ophthalmol. 1988;85:514–516
  17. Branch Vein Occlusion Study Group. Argon laser photocoagulation for macular edema in branch vein occlusion. Am J Ophthalmol. 1984;98:271–282
  18. Cekic O, Chang S, Tseng JJ, et al. Intravitreal triamcinolone injection for treatment of macular edema secondary to branch retinal vein occlusion. Retina. 2005;25:851–855
  19. Chen SDM, Sundaram V, Lockhead J, Patel CK. Intravitreal triamcinolone for the treatment of ischemic macular edema associated with branch retinal vein occlusion. Am J Ophthalmol. 2006;141:876–883
  20. Patel PJ, Zaheer I, Karia N. Intravitreal triamcinolone acetonide for macular oedema owing to retinal vein occlusion. Eye. 2008;22:60–64
  21. Cakir M, Dogan M, Bayraktar S, et al. Efficacy of intravitreal triamcinolone for the treatment of macular edema secondary to branch retinal vein occlusion in eyes with or without grid laser photocoagulation. Retina. 2008;28:465–472
  22. Osterloh MD, Charles S. Surgical decompression of branch retinal vein occlusions. Arch Ophthalmol. 1988;106:1469–1471
  23. Yamamoto S, Saito W, Yagi F, Takeuchi S, Sato E, Mizunoya S. Vitrectomy with or without arteriovenous adventitial sheathotomy for macular edema associated with branch retinal vein occlusion. Am J Ophthalmol. 2004;138:907–914
  24. Starita C, Patel M, Katz B, Adamis AP. Vascular endothelial growth factor and the potential therapeutic use of pegaptanib (Macugen) in diabetic retinopathy. Dev Ophthalmol. 2007;39:122–148
  25. Senger DR, Connolly DT, Van de Water L, Feder J, Dvorak HF. Purification and NH2-terminal amino acid sequence of guinea pig tumor-secreted vascular permeability factor. Cancer Res. 1990;50:1774–1778
  26. Ferrara N. Vascular endothelial growth factor: basic science and clinical progress. Endocr Rev. 2004;25:581–611
  27. Noma H, Minamoto A, Funatsu H, et al. Intravitreal levels of vascular endothelial growth factor and interleukin-6 are correlated with macular edema in branch retinal vein occlusion. Graefes Arch Clin Exp Ophthalmol. 2006;244:309–315
  28. Noma H, Funatsu H, Yamasaki M, et al. Aqueous humour levels of cytokines are correlated to vitreous levels and severity of macular oedema in branch retinal vein occlusion. Eye. 2008;22:42–48
  29. Boyd SR, Zachary I, Chakravarthy U, et al. Correlation of increased vascular endothelial growth factor with neovascularization and permeability in ischemic central vein occlusion. Arch Ophthalmol. 2002;120:1644–1650
  30. Ng EW, Adamis AP. Targeting angiogenesis, the underlying disorder in neovascular age-related macular degeneration. Can J Ophthalmol. 2005;40:352–368
  31. Ng EW, Shima DT, Calias P, Cunningham ET, Guyer DR, Adamis AP. Pegaptanib, a targeted anti-VEGF aptamer for ocular vascular disease. Nat Rev Drug Discov. 2006;5:123–132
  32. Gragoudas ES, Adamis AP, Cunningham ET, Feinsod M, Guyer DR. Pegaptanib for neovascular age-related macular degeneration. N Engl J Med. 2004;351:2805–2816
  33. Cunningham ET, Adamis AP, Altaweel M, et al. A phase II randomized double-masked trial of pegaptanib, an anti-vascular endothelial growth factor aptamer, for diabetic macular edema. Ophthalmology. 2005;112:1747–1757
  34. Adamis AP, Altaweel M, Bressler NM, et al. Macugen Diabetic Retinopathy Study Group Changes in retinal neovascularization after pegaptanib (Macugen) therapy in diabetic individuals. Ophthalmology. 2006;113:23–28
  35. Wroblewski JJ, Wells JA, Adamis AP, et al. Pegaptanib sodium for macular edema secondary to central retinal vein occlusion. Arch Ophthalmol. 2009;127:374–380
  36. Mechtcheriakova D, Wlachos A, Holzmüller H, Binder BR, Hofer E. Vascular endothelial cell growth factor-induced tissue factor expression in endothelial cells is mediated by EGR-1. Blood. 1999;93:3811–3823
  37. Sassa Y, Hata Y, Murata T, et al. Functional role of Egr-1 mediating VEGF-induced tissue factor expression in the retinal capillary endothelium. Graefes Arch Clin Exp Ophthalmol. 2002;240:1003–1010
  38. Prager F, Michels S, Kriechbaum K, et al. Intravitreal bevacizumab (Avastin) for macular oedema secondary to retinal vein occlusion: 12-month results of a prospective clinical trial. Br J Ophthalmol. 2008;92:518–522
  39. Kreutzer TC, Alge CS, Wolf AH, et al. Intravitreal bevacizumab for the treatment of macular oedema secondary to branch retinal vein occlusion. Br J Ophthalmol. 2008;92:351–355
  40. Jaissle GB, Leitritz M, Gelisken F, Ziemssen F, Bartz-Schmidt KU, Szurman P. One-year results after intravitreal bevacizumab for macular edema secondary to branch retinal vein occlusion. Graefes Arch Clin Exp Ophthamol. 2009;247:27–33
  41. Campochiaro PA, Hafiz G, Shah SM, et al. Ranibizumab for macular edema due to retinal vein occlusions; implication of VEGF as a critical stimulator. Mol Ther. 2008;16:791–799
  42. Rabena MD, Pieramici DJ, Castellarin AA, Nasir MA, Avery RL. Intravitreal bevacizumab (Avastin) in the treatment of macular edema secondary to branch retinal vein occlusion. Retina. 2007;27:419–425
  43. Wu L, Arevalo JF, Roca JA, et al. Comparison of two doses of intravitreal bevacizumab (Avastin) for the treatment of macular edema secondary to branch retinal vein occlusion: results from the Pan-American Collaborative Retina Study Group at 6 months of follow-up. Retina. 2008;28:212–219
  44. Gregori NZ, Rattan GH, Rosenfeld PJ, et al. Safety and efficacy of intravitreal bevacizumab (Avastin) for the management of branch and hemiretinal vein occlusion. Retina. 2009;29:913–925
  45. Brown DM, Kaiser PK, Michels M, et al. Ranibizumab versus verteporfin for neovascular age-related macular degeneration. N Engl J Med. 2006;355:1432–1444
  46. Rosenfeld PJ, Brown DM, Heier JS, et al. MARINA Study Group Ranibizumab for neovascular age-related macular degeneration. N Engl J Med. 2006;355:1419–1431
  47. Ferrara N, Damico L, Shams N, Lowman H, Kim R. Development of ranibizumab, an anti-vascular endothelial growth factor antigen binding fragment, as therapy for neovascular age-related macular degeneration. Retina. 2006;26:859–870
  48. Ishida S, Usui T, Yamashiro K, Kaji Y, et al. VEGF164 is proinflammatory in the diabetic retina. Invest Ophthalmol Vis Sci. 2003;44:2155–2162
  49. Ishida S, Usui T, Yamashiro K, et al. VEGF164-mediated inflammation is required for pathological, but not physiological, ischemia-induced retinal neovascularization. J Exp Med. 2003;198:483–489
  50. Kamba T, Tam BY, Hashizume H, et al. VEGF-dependent plasticity of fenestrated capillaries in the normal adult microvasculature. Am J Physiol Heart Circ Physiol. 2006;290:H560–H576
  51. Blaauwgeers HG, Holtkamp GM, Rutten H, et al. Polarized vascular endothelial growth factor secretion by human retinal pigment epithelium and localization of vascular endothelial growth factor receptors on the inner choriocapillaris (Evidence for a trophic paracrine relation). Am J Pathol. 1999;155:421–428
  52. Nishijima K, Ng YS, Zhong L, et al. Vascular endothelial growth factor-A is a survival factor for retinal neurons and a critical neuroprotectant during the adaptive response to ischemic injury. Am J Pathol. 2007;171:53–67
  53. Klein R, Klein BE, Moss SE, Meuer SM. The epidemiology of retinal vein occlusion: the Beaver Dam Eye Study. Trans Am Ophthalmol Soc. 2000;98:133–141
  54. Hayreh SS, Zimmerman B, McCarthy MJ, Podhajsky P. Systemic diseases associated with various types of retinal vein occlusion. Am J Ophthalmol. 2001;131:61–77
  55. Ueta T, Yanagi Y, Tamaki Y, Yamaguchi T. Cerebrovascular accidents in ranibizumab. Ophthalmology. 2009;116:362
  56. Singerman LJ, Masonson H, Patel M, et al. Pegaptanib sodium for neovascular age-related macular degeneration: third-year safety results of the V.I.S.I.O.N. trial. Br J Ophthalmol. 2008;92:1606–1611
  57. Esrick E, Subramanian ML, Heier JS, et al. Multiple laser treatments for macular edema attributable to branch retinal vein occlusion. Am J Ophthalmol. 2005;139:653–657

PII: S0002-9394(09)00553-4

doi: 10.1016/j.ajo.2009.08.005

American Journal of Ophthalmology
Volume 149, Issue 1 , Pages 147-154 , January 2010

Article Tools

* Image Usage & Resolution